Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study-Reference-Cited by-同舟云学术

Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study

Published:2018-02-15 Issue:21 Volume:9 Page:15542-15551
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Fujimura Taku¹,Sato Yota¹,Tanita Kayo¹,Kambayashi Yumi¹,Otsuka Atsushi²,Fujisawa Yasuhiro³,Yoshino Koji⁴,Matsushita Shigeto⁵,Funakoshi Takeru⁶,Hata Hiroo⁷,Yamamoto Yuki⁸,Uchi Hiroshi⁹,Nonomura Yumi²,Tanaka Ryota³,Aoki Megumi⁵,Imafuku Keisuke⁷,Okuhira Hisako⁸,Furudate Sadanori¹,Hidaka Takanori¹,Aiba Setsuya¹

Affiliation:

1. Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan

2. Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan

3. Department of Dermatology, Faculty of University of Tsukuba, Tsukuba, Japan

4. Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Tokyo, Japan

5. Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan

6. Department of Dermatology, Keio University School of Medicine, Tokyo, Japan

7. Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

8. Department of Dermatology, Wakayama Medical University, Wakayama, Japan

9. Department of Dermatology, Kyushu University Graduate School of Medicine, Fukuoka, Japan

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors;Cancers;2024-03-20

2. Pulmonary toxicity of immune checkpoint immunotherapy;Journal of Clinical Investigation;2024-01-16

3. Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors;Japanese Journal of Clinical Oncology;2024-01-05

4. Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers;International Journal of Biological Sciences;2024

5. Lipidomics reveals immune-related adverse events in NSCLC patients receiving immune checkpoint inhibitor;International Immunopharmacology;2024-01